Literature DB >> 1603118

Endothelial dysfunction in pulmonary hypertension.

J Loscalzo.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1603118     DOI: 10.1056/NEJM199207093270209

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  22 in total

1.  Characterization of von Willebrand factor in primary pulmonary hypertension.

Authors:  M T Collados; J Sandoval; S López; F A Massó; A Páez; J R Borbolla; L F Montaño
Journal:  Heart Vessels       Date:  1999       Impact factor: 2.037

2.  Impairment of endothelium-dependent pulmonary vasodilation in patients with primary pulmonary hypertension.

Authors:  S J Brett; J Simon; R Gibbs; J R Pepper; T W Evans
Journal:  Thorax       Date:  1996-01       Impact factor: 9.139

Review 3.  Pulmonary hypertension in chronic obstructive pulmonary disease: current theories of pathogenesis and their implications for treatment.

Authors:  J L Wright; R D Levy; A Churg
Journal:  Thorax       Date:  2005-07       Impact factor: 9.139

4.  Acetylcholine causes dose dependent increase in pulmonary flow in patients with chronic heart failure and elevated pulmonary vascular resistance.

Authors:  F X Kleber; R Wensel; S B Felix; I Reindl; G Baumann
Journal:  Basic Res Cardiol       Date:  1996 Sep-Oct       Impact factor: 17.165

Review 5.  How valid are animal models to evaluate treatments for pulmonary hypertension?

Authors:  Maria E Campian; Maxim Hardziyenka; Martin C Michel; Hanno L Tan
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-09       Impact factor: 3.000

6.  Systemic arterial endothelial function in children and young adults with idiopathic pulmonary arterial hypertension: is there a relation to pulmonary endothelium-dependent relaxation?

Authors:  Heiner Latus; Anna Werz; Ines Kock; Stefan Rupp; Gunter Kerst; Joachim Kreuder; Dietmar Schranz; Christian Apitz
Journal:  Pediatr Cardiol       Date:  2014-01-19       Impact factor: 1.655

7.  L-arginine infusion has no effect on systemic haemodynamics in normal volunteers, or systemic and pulmonary haemodynamics in patients with elevated pulmonary vascular resistance.

Authors:  S V Baudouin; P Bath; J F Martin; R Du Bois; T W Evans
Journal:  Br J Clin Pharmacol       Date:  1993-07       Impact factor: 4.335

8.  Bosentan inhibits oxidative and nitrosative stress and rescues occlusive pulmonary hypertension.

Authors:  Olga Rafikova; Ruslan Rafikov; Sanjiv Kumar; Shruti Sharma; Saurabh Aggarwal; Frank Schneider; Danny Jonigk; Stephen M Black; Stevan P Tofovic
Journal:  Free Radic Biol Med       Date:  2012-11-29       Impact factor: 7.376

Review 9.  Recognition and management of pulmonary hypertension.

Authors:  J C Wanstall; T K Jeffery
Journal:  Drugs       Date:  1998-12       Impact factor: 9.546

Review 10.  RhoA/Rho-kinase signaling: a therapeutic target in pulmonary hypertension.

Authors:  Scott A Barman; Shu Zhu; Richard E White
Journal:  Vasc Health Risk Manag       Date:  2009-08-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.